Skip to main content

Volume 14 Supplement 6

Viral Hepatitis and Drug Use in Europe

Research and Commentaries

Edited by Jeffrey V Lazarus and Kevin A Fenton

This publication has been produced with the financial support of the Drug Prevention and Information Programme (DPIP) of the European Union. The contents of this publication are the sole responsibility of the authors and can in no way be taken to reflect the view of the European Commission. The publication charges for this supplement were funded by AbbVie as an unresitricted grant to Rigshospitalet, the University of Copenhagen, Denmark. AbbVie further co-funded the printing of the supplement. The peer review process was overseen by the Supplement Editors in accordance with BioMed Central's peer review guidelines for supplements. The Supplement Editors declare that they have no competing interests.

 Read the blog related to this supplement.

  1. Behavioural surveillance among people who inject drugs (PWID) and testing for hepatitis C virus (HCV) and HIV is needed to understand the scope of both epidemics in at-risk populations and to suggest steps to ...

    Authors: Robert Heimer, Ksenia Eritsyan, Russell Barbour and Olga S Levina
    Citation: BMC Infectious Diseases 2014 14(Suppl 6):S12
  2. Hepatitis C virus (HCV) infection represents a major global health problem, which in high-income countries now mostly affects people who inject drugs (PWID). Many studies show that the treatment of HCV infecti...

    Authors: Mojca Maticic, Jerneja Videcnik Zorman, Sergeja Gregorcic, Eberhard Schatz and Jeffrey V Lazarus
    Citation: BMC Infectious Diseases 2014 14(Suppl 6):S14
  3. Unsafe injections, through infectious bodily fluids, are a major route of transmission for hepatitis B and C. Viral hepatitis burden among people who inject drugs is particularly high in many Member States of ...

    Authors: Alexander Spina, Irina Eramova and Jeffrey V Lazarus
    Citation: BMC Infectious Diseases 2014 14(Suppl 6):S15
  4. Fifteen million adults in the World Health Organization European Region are estimated to have active hepatitis C infection. Intravenous drug use is a major hepatitis C transmission route in this region, and pe...

    Authors: Jeffrey V Lazarus, Ida Sperle, Mojca Maticic and Lucas Wiessing
    Citation: BMC Infectious Diseases 2014 14(Suppl 6):S16
  5. Authors: Jeffrey V Lazarus, Jens Lundgren, Jordi Casabona, Lucas Wiessing, Catharina Matheï, Peter Vickerman, Maria Prins, Mirjam Kretzschmar, Maria Kantzanou, Isabelle Giraudon, Marica Ferri, Paul Griffiths, Magdalena Harris, Margaret Walker, Lilyana Chavdarova, Eberhard Schatz…
    Citation: BMC Infectious Diseases 2014 14(Suppl 6):S18

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 3.4
    5-year Journal Impact Factor: 3.3
    Source Normalized Impact per Paper (SNIP): 1.106
    SCImago Journal Rank (SJR): 1.031

    Speed 2023
    Submission to first editorial decision (median days): 13
    Submission to acceptance (median days): 148

    Usage 2023
    Downloads: 6,949,317
    Altmetric mentions: 28,444

Peer-review Terminology

  • The following summary describes the peer review process for this journal:

    Identity transparency: Single anonymized

    Reviewer interacts with: Editor

    Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication

    More information is available here

Sign up for article alerts and news from this journal